Under 10% of people who could benefit from obesity jabs including Wegovy are able to get them, states the global health agency as it issues its inaugural guidance on the medications.
Given more than one billion individuals worldwide now living with obesity, it is advocating for broader and more equitable access to these injectable treatments.
According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a long-term condition that can be addressed with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major obstacles to broad availability to the jabs that can help people shift substantial body mass, notes the organization.
GLP-1 Therapy Supply Crisis
Despite the current most favorable case, the manufacturing of such drugs would only suffice for around 100 million people – under 10% of eligible patients, as stated by the health organization.
The guideline calls on governments and firms to expand access, via approaches including voluntary licensing.
The intellectual property rights on a key compound – the primary ingredient of a leading brand – is due to expire in multiple nations in 2026.
The Way Obesity Jabs Work
These medications imitate a natural hormone to reduce digestion speed, suppress the appetite and increase the sense of being full so people eat less.
Individuals typically begin shedding pounds in the initial weeks of beginning the weekly injections.
Studies indicates people may see weight return after a year of stopping the treatment, because their normal food cravings resume.
Being overweight or obese elevates your chance for experiencing diseases, like diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight concerns people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.
